Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Non-Hodgkin 15Lymphoma 15Leukemia, B-Cell 14Leukemia 14Lymphoma, Follicular 11Recurrence 9Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Mantle-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Lymphoma, B-Cell 4Bronchiolitis Obliterans Syndrome 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 2Hematologic Neoplasms 2Thrombocytopenia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × ofatumumab × Clear all
NCT01376713 2015-10-06

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

Medical University of Vienna

Phase 2 Completed
10 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡